Integrate guideline-directed molecular testing strategies in clinical practice to identify patients with NSCLC most likely to benefit from HER2-targeted agents Evaluate the safety and efficacy of FDA approved and investigational HER2-targeted agents for the treatment of HER2-mutant NSCLC Incorporate strategies to mitigate treatment-related adverse events unique to HER2-targeted agents
- Provider:HMP Education
- Activity Link: https://www.hmpeducation.com/program/24-gdulc-102-2
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - MOC Credit Details: ABS - 0.75 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False Source: Boehringer Ingelheim Pharmaceuticals, Inc. - Amount: 0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest